Crotedumab 产品活性：Crotedumab (REGN1193) 是一种人源的 IgG4 单克隆抗体，可结合并抑制胰高血糖素受体 (GCGR)，KD 值为 0.1 nM。Crotedumab 可用于糖尿病的研究。 产品来源： https://www.medchemexpress.cn/crotedumab.html 研究领域：GPCR/G Protein 作用靶点：GCGR In Vitro: Crotedumab binds to GCGR from multiple species (mouse, rat, monkey, and humans) with high affinity (KD=0.03 nM-0.39 nM). Crotedumab inhibits Glucagon-induced signaling through GCGR with IC50s of 0.65, 3.2, 0.94 and 1.0 nM in HEK293 cells transfected with GCGR from human, monkey, mouse, and rat, respectively. In Vivo: Crotedumab (3-30 mg/kg; s.c. once weekly for 4 weeks) reduces blood glucose and body weight and induces reversible hyperglucagonemia and α-cell hyperplasia in DIO C57BL/6 mice. Crotedumab (10 mg/kg; a single s.c.) markedly decreases blood glucose for 18 days in diabetic ob/ob mice. REGN1193 (20 mg/kg; a single i.v.) produces a robust reduction in overnight-fasted blood glucose in both the conscious and anesthetized state of diabetic cynomolgus monkeys as well as in blood glucose measured 1 hour after feeding. 相关产品：Semaglutide | Exendin-4 | Liraglutide | Glucagon (1-29), bovine, human | Exendin(9-39) amide | Retatrutide | Orforglipron | GLP-1(7-37) | GLP-1(7-36), amide acetate | MK 0893 | Adomeglivant | BETP | Cotadutide acetate | GLP-1R Antagonist 1 | Danuglipron | GLP-1(9-36)amide | GLP-2(1-33)(human) | Oxyntomodulin (bovine, porcine) | Lixisenatide | Beinaglutide | Lotiglipron | Survodutide | NNC-0640 | Mazdutide | GLP-1R agonist 2 | LGD-6972 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。